WHO Designates Resomelagon as Key Dengue Drug Candidate

The World Health Organization has identified resomelagon, an oral pro-resolution therapy, as one of six dengue drug candidates warranting further clinical development. This designation follows a comprehensive review of the global dengue treatment pipeline published in Lancet Microbe. Resomelagon is notable as the sole host-directed therapy among the selected candidates, highlighting a potential new approach to dengue treatment.